Collaborating partners

Our research group collaborates with the Eudragene project, a European research project in which data and DNA from patients who have experienced rare serious type B reactions are collected. This project aims to investigate genetic determinants of seven specific serious ADRs; Torsade de Pointes associated with long QT syndrome, myopathy/rhabdomyolysis caused by statins or fibrates, agranulocytosis, tendon rupture/tendinitis caused by fluoroquinolones, liver injury, acute psychosis caused by mefloquine, and Stevens-Johnson syndrome. Within the 7th Framework Program, headed by Prof Colin Palmer of the University of Dundee, we also collaborate with several European researchers, focusing on ACE-inhibitor induced angioedema and statin-induced myopathy.

Other collaborators include the US-based International Serious Adverse Event Consortium (iSAEC), which focuses on drug-induced liver injury, serious skin reactions, and bisphosphonate-induced osteonecrosis of the jaw. National collaborators include specialists in rheumatology at Uppsala University Hospital studying the genetic basis of methotrexate-induced liver injury, and specialists in obesity-related disease, which is commonly induced by antidepressants or neuroleptics.

For adverse reactions to covid-19 vaccines, we collaborate with Science for Life Laboratory at Karolinska institute, and with the Department of Medical Biochemistry and Microbiology at Uppsala University.